Xencor, Inc. (NASDAQ:XNCR) VP Sells $1,612,700.32 in Stock

Xencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $23.48, for a total value of $1,612,700.32. Following the transaction, the vice president now owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Xencor Stock Down 0.4 %

Shares of XNCR stock traded down $0.10 during trading hours on Wednesday, reaching $23.61. The company had a trading volume of 652,856 shares, compared to its average volume of 597,461. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 1-year low of $15.31 and a 1-year high of $26.84. The company has a 50 day moving average of $20.70 and a 200 day moving average of $20.34.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. During the same period last year, the firm posted ($0.40) earnings per share. The business’s quarterly revenue was down 81.9% compared to the same quarter last year. On average, analysts anticipate that Xencor, Inc. will post -3.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on XNCR shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Royal Bank of Canada lifted their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. JPMorgan Chase & Co. increased their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Wedbush reissued an “outperform” rating and set a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Xencor has a consensus rating of “Moderate Buy” and a consensus price target of $35.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Texas Permanent School Fund Corp lifted its holdings in shares of Xencor by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company’s stock valued at $1,179,000 after purchasing an additional 690 shares in the last quarter. Linden Thomas Advisory Services LLC boosted its holdings in shares of Xencor by 1.6% in the second quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock valued at $826,000 after buying an additional 699 shares during the period. Baillie Gifford & Co. increased its position in shares of Xencor by 3.3% during the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock worth $445,000 after acquiring an additional 744 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Xencor by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 900 shares during the period. Finally, Diversified Trust Co lifted its position in Xencor by 7.8% in the 2nd quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 1,017 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.